Thomas J. Saphner
Expertise in
11
conditions

Dr. Thomas J. Saphner

Hematology | Oncology
5300 Memorial Dr, 
Two Rivers, WI 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
5300 Memorial Dr, 
Two Rivers, WI 

Overview

Thomas Saphner is a Hematologist and an Oncologist in Two Rivers, Wisconsin. Dr. Saphner is highly rated in 11 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Upper Tract Urothelial Carcinoma (UTUC), Inflammatory Breast Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency

University of Kentucky

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MI

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Wisconsin Hospital and Clinics, Medical Oncology

Hospital Affiliations

Bay Area Medical Center
Aurora Health Care Central Inc
Aurora Baycare Medical Ctr
Aurora Medical Ctr Manitowoc County

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Vince Lombardi Cancer Clinic
5300 Memorial Dr, Two Rivers, WI 54241
Other Locations
Aurora Cancer Care
3003 University Dr, Marinette, WI 54143
Vince Lombardi Cancer Clinic
855 N Westhaven Dr, Oshkosh, WI 54904

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: January 26, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Other
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
Enrollment Status: Completed
Publish Date: February 04, 2026
Intervention Type: Procedure
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
EROS: Engendering Reproductive Health Within Oncologic Survivorship
EROS: Engendering Reproductive Health Within Oncologic Survivorship
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other
Study Phase: Not Applicable
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Other, Drug
Study Phase: Not Applicable
Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Other, Drug
Study Drug: Ibuprofen
Study Phase: Phase 2
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: Donepezil 
Study Phase: Phase 3
View 14 Less Clinical Trials

18 Total Publications

A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study.
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study.
Journal: Journal of health psychology
Published: July 28, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Shannon Schmidt
Hematology | Oncology
Expertise in
39
conditions
Dr. Shannon Schmidt
Hematology | Oncology

Thedacare Regional Medical Center-Appleton Inc.

2500 E Capitol Dr, 
Appleton, WI 
 (42.8 miles away)
920-364-3600
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Shannon Schmidt is a Hematologist and an Oncologist in Appleton, Wisconsin. Dr. Schmidt has been practicing medicine for over 17 years is highly rated in 39 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, B-Cell Lymphoma, Angiosarcoma, and Bone Marrow Aspiration.

Kun Xiao
Expertise in
11
conditions
Dr. Kun Xiao
Hematology | Oncology
Expertise in
11
conditions
Dr. Kun Xiao
Hematology | Oncology

Vince Lombardi Cancer Clinic

1222 N 23rd St, 
Sheboygan, WI 
 (11.6 miles away)
920-457-6800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kun Xiao is a Hematologist and an Oncologist in Sheboygan, Wisconsin. Dr. Xiao is highly rated in 11 conditions, according to our data. His top areas of expertise are Appendix Cancer, Essential Thrombocythemia, Chronic Lymphocytic Leukemia (CLL), Small Cell Lung Cancer (SCLC), and Bone Marrow Transplant.

Zahid Dar
Expertise in
33
conditions
Dr. Zahid Dar
Hematology | Oncology
Expertise in
33
conditions
Dr. Zahid Dar
Hematology | Oncology

Vince Lombardi Cancer Clinic

855 N Westhaven Dr, 
Oshkosh, WI 
 (36.7 miles away)
920-456-7870
Languages Spoken:
English, Hindi, Urdu
See accepted insurances

Zahid Dar is a Hematologist and an Oncologist in Oshkosh, Wisconsin. Dr. Dar is highly rated in 33 conditions, according to our data. His top areas of expertise are Metastatic Pleural Tumor, Paget Disease of the Breast, Familial Pancreatic Cancer, and Pleuropulmonary Blastoma.

Frequently Asked Questions about Dr. Thomas J. Saphner

How do I make an appointment with Dr. Thomas J. Saphner?

You can book an appointment with Dr. Thomas J. Saphner by calling their office at 920-793-6100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas J. Saphner a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas J. Saphner is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas J. Saphner specialize in?

While Dr. Thomas J. Saphner is a Hematology, they have specific expertise in Paget Disease of the Breast, Upper Tract Urothelial Carcinoma (UTUC), and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Thomas J. Saphner participate in research or clinical trials?

Yes. Dr. Thomas J. Saphner has published 18 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Thomas J. Saphner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas J. Saphner accept my insurance?

Dr. Thomas J. Saphner accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 920-793-6100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saphner's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile